Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Details Narrative)

v3.21.2
Stockholders’ Equity (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 30, 2021
Mar. 15, 2021
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Feb. 23, 2021
Class of Stock [Line Items]                  
Stock Issued During Period, Value, Conversion of Convertible Securities              
Fair Value Adjustment of Warrants       $ (214,000)    
Preferred Stock Warrants [Member]                  
Class of Stock [Line Items]                  
Stock Issued During Period, Shares, Conversion of Convertible Securities           43,107      
Merger Agreement [Member]                  
Class of Stock [Line Items]                  
[custom:WarrantsAndRightsIssued-0]     2,157,686     $ 2,157,686      
Merger Agreement [Member] | Investor [Member]                  
Class of Stock [Line Items]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                 143,890
Class of Warrant or Right, Exercise Price of Warrants or Rights                 $ 5.9059
Fair Value Adjustment of Warrants           214,000      
[custom:WarrantsFairValueDisclosure-0]     $ 421,000     $ 421,000      
Series A Convertible Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Temporary Equity, Shares Outstanding     0     0   4,611,587  
Stock Issued During Period, Shares, Conversion of Convertible Securities               5,973,509  
Series B Convertible Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Temporary Equity, Shares Outstanding     0     0   3,489,470  
Stock Issued During Period, Shares, Conversion of Convertible Securities               4,524,171  
Series B Convertible Preferred Stock [Member] | Merger Agreement [Member] | Cancer Genetics Inc [Member]                  
Class of Stock [Line Items]                  
Stock Issued During Period, Value, Conversion of Convertible Securities   $ 2,000,000.0              
Series B Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Stock Issued During Period, Shares, Conversion of Convertible Securities         468,000   468,000    
Sale of Stock, Number of Shares Issued in Transaction       235,877          
Sale of Stock, Consideration Received on Transaction       $ 1,250,000          
Stock Issued During Period, Value, Conversion of Convertible Securities         $ 2,588,000   $ 2,569,000    
Series C Convertible Preferred Stock [Member] | Merger Agreement [Member] | Cancer Genetics Inc [Member]                  
Class of Stock [Line Items]                  
Stock Issued During Period, Shares, Conversion of Convertible Securities 699,395